Aardvark Therapeutics (AARD) Income Statement (2024 - 2026)
Income Statement report data from Mar 31, 2024 to Mar 31, 2026 for Aardvark Therapeutics (AARD).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | |
|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||
Total Revenue | - | -2.84M | 1.35M (-9.40%) | 1.49M | - | 720K (-28.00%) | 1.00M (+69.49%) | 590K (+490.00%) | 100K |
Operating Expenses | |||||||||
Research And Development | 17M (+15.87%) | 14M (+4.08%) | 14M (+4.49%) | 13M (+69.46%) | 7.76M (-3.72%) | 8.06M (+98.03%) | 4.07M (+0.99%) | 4.03M (+233.06%) | 1.21M |
Selling General And Administrative | 5.90M (+33.79%) | 4.41M (+11.08%) | 3.97M (+47.04%) | 2.70M (-0.74%) | 2.72M (+95.68%) | 1.39M (+34.95%) | 1.03M (-49.26%) | 2.03M (+136.05%) | 860K |
Operating Expenses | 22M (+20.11%) | 19M (+5.65%) | 18M (+11.67%) | 16M (+51.38%) | 10M (+10.79%) | 9.45M (+85.66%) | 5.09M (-16.14%) | 6.07M (+179.72%) | 2.17M |
Depreciation And Amortization | 10K (-66.67%) | 30K | - | - | 10K (0.00%) | 10K | - | - | - |
Operating Income | |||||||||
Operating Income | -22.46M (+20.11%) | -18.70M (+5.65%) | -17.70M (+11.67%) | -15.85M (+51.38%) | -10.47M (+10.79%) | -9.45M (+85.66%) | -5.09M (-16.14%) | -6.07M (+179.72%) | -2.17M |
Ebit | -22.46M (+20.11%) | -18.70M (+5.65%) | -17.70M (+11.67%) | -15.85M (+51.38%) | -10.47M (+10.79%) | -9.45M (+85.66%) | -5.09M (-16.14%) | -6.07M (+179.72%) | -2.17M |
EBITDA | -22.45M (+4.22%) | -21.54M (+31.99%) | -16.32M (+13.57%) | -14.37M (+37.38%) | -10.46M (-4.65%) | -10.97M (+162.44%) | -4.18M (-23.30%) | -5.45M (+151.15%) | -2.17M |
Other Income / Expenses | |||||||||
Other Non Operating Income | 880K (-82.85%) | 5.13M (+269.06%) | 1.39M (-6.08%) | 1.48M (+27.59%) | 1.16M (-47.27%) | 2.20M (+141.76%) | 910K (+46.77%) | 620K | -10.00K |
Net Income | |||||||||
Net Income From Continuing Operations | -21.59M (+22.67%) | -17.60M (+7.84%) | -16.32M (+13.57%) | -14.37M (+54.35%) | -9.31M (+6.04%) | -8.78M (+110.05%) | -4.18M (-23.30%) | -5.45M (+150.00%) | -2.18M |
Net Income | -21.59M (+22.67%) | -17.60M (+7.84%) | -16.32M (+13.57%) | -14.37M (+54.35%) | -9.31M (+6.04%) | -8.78M (+110.05%) | -4.18M (-23.30%) | -5.45M (+150.00%) | -2.18M |
Comprehensive Income Net Of Tax | -21.65M (-62.35%) | -57.51M (+254.34%) | -16.23M (+12.63%) | -14.41M (+55.45%) | -9.27M (-54.98%) | -20.59M (+392.58%) | -4.18M (-23.30%) | -5.45M (+150.00%) | -2.18M |